Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis

Journal of Clinical Gastroenterology

Volumn 48, Issue 4, 2014, Pages 351-355

  Sura, Siddharth P ^a   Ahmed, Awais ^b   Cheifetz, Adam S ^b   Moss, Alan C ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Crohn's disease; diagnostics; indeterminate colitis; ulcerative colitis

Indexed keywords

FUNGUS ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN C ANTIBODY; PROTEIN ANTIBODY; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL FEATURE; COLITIS; COLON RESECTION; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOLOGY TEST KIT; INDETERMINATE COLITIS; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROLOGY; ULCERATIVE COLITIS;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, BACTERIAL; ANTIBODIES, FUNGAL; BACTERIAL OUTER MEMBRANE PROTEINS; COLITIS; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PORINS; SACCHAROMYCES CEREVISIAE; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS;

EID: 84896317375     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000083     Document Type: Article

References (31)

1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-523
2. Sands BE. From symptom to diagnosis: Clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004;126:1518-1532
3. Sandborn WJ. Serologic markers in inflammatory bowel disease: State of the art. Rev Gastroenterol Disord. 2004;4: 167-174
4. Geboes K, Colombel JF, Greenstein A, et al. Indeterminate colitis: A review of the concept-what's in a name? Inflamm Bowel Dis. 2008;14:850-857
5. Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease-colitis indeterminate. J Clin Pathol. 1978;31:567-577
6. Tremaine WJ. Review article: Indeterminate colitis- definition, diagnosis and management. Aliment Pharmacol Ther. 2007;25:13-17
7. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36
8. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut. 2006;55:749-753
9. Geboes K, De Hertogh G. Indeterminate colitis. Inflamm Bowel Dis. 2003;9:324-331
10. Tremaine WJ. Is indeterminate colitis determinable? Curr Gastroenterol Rep. 2012;14:162-165
11. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: A prospective followup study. Gastroenterology. 2002;122:1242-1247
12. Vermeire S, Joossens S, Peeters M, et al. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology. 2001;120: 827-833
13. Davis MK, Andres JM, Jolley CD, et al. Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis. J Pediatr Gastroenterol Nutr. 2007;45:409-413
14. Lennard-Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol. 1997;9:353-359
15. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Gut. 2006;55(suppl 1):i1-15
16. Vermeulen N, Vermeire S, Rutgeerts P, et al. Likelihood ratio for Crohn's disease as a function of anti-Saccharomyces cerevisiae antibody concentration. Inflamm Bowel Dis. 2010;16:5-6
17. Dubinsky MC. Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease. World J Gastroenterol. 2010;16:2604-2608
18. Anand V, Russell AS, Tsuyuki R, et al. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis. Can J Gastroenterol. 2008;22:33-36
19. Kaila B, Orr K, Bernstein CN. The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: Accurate in identifying cases of Crohn's disease and predicting inflammatory disease. Can J Gastroenterol. 2005;19:717-721
20. Koutroubakis IE, Petinaki E, Mouzas IA, et al. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:449-454
21. Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96:730-734
22. Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: Prevalence and diagnostic role. Gut. 1998;42:788-791
23. Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103:665-681
24. Peyrin-Biroulet L, Standaert-Vitse A, Branche J, et al. IBD serological panels: Facts and perspectives. Inflamm Bowel Dis. 2007;13:1561-1566
25. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005;128:2020-2028
26. Mokrowiecka A, Daniel P, Slomka M, et al. Clinical utility of serological markers in inflammatory bowel disease. Hepatogastroenterology. 2009;56:162-166
27. Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006;101:2410-2422
28. Joossens S, Colombel JF, Landers C, et al. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut. 2006;55:1667-1669
29. Moum B, Ekbom A, Vatn MH, et al. Inflammatory bowel disease: Re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. Gut. 1997; 40:328-332
30. McGee S. Simplifying likelihood ratios. J Gen Intern Med. 2002;17:646-649
31. Farmer M, Petras RE, Hunt LE, et al. The importance of diagnostic accuracy in colonic inflammatory bowel disease. Am J Gastroenterol. 2000;95:3184-3188 Kidney Diseases